AVIR Atea Pharmaceuticals, Inc. Insider Trading

Director Murphy Polly A. purchased 6,100 shares of AVIR at $4.17, increasing holdings to 92,145 shares amid 30-day decline of -26.6%.

Director Murphy Polly A. purchased 6,100 shares at $4.17, expanding her position from 86,045 to 92,145 shares (+7.1% increase). The transaction occurs as the stock trades at $4.19, down -26.6% over the past 30 days and -35.0% from its 52-week high of $6.45. Atea Pharmaceuticals remains unprofitable, with net income of $-45,440,000.00 in its most recent full fiscal year, though revenue reached $32,811,000.00 last quarter and shows strong annual growth of +622.5%. The purchase represents a substantive addition to holdings during a period of significant price weakness and ongoing losses at the company level.